Foley & Lardner LLP Partner Kyle Faget was quoted in the MedTech Dive article, “3 key FDA topics for medtechs in 2022,” about the October 2021 release of the FDA’s list of proposed draft and final medical device guidance documents for fiscal year 2022, including the final guidance on clinical decision support (CDS) software.
Faget said that “The risk-based approach to enforcement that FDA issued previously is not easy for [technology] developers to follow. FDA needs to provide more clarity for developers as to where the boundaries are for each one of those categories.”
Faget is co-chair of Foley’s Health Care and Life Sciences Practice Groups.
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.